<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies</h1>

    <table>
      <tr><th>Ticker</th><td>PFSA</td></tr>
      <tr><th>Float</th><td>1.1 M</td></tr>
      <tr><th>IO</th><td>5.15%</td></tr>
      <tr><th>MC</th><td>3.7 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Profusa (NASDAQ: PFSA) entered a know-how collaboration with Mayo Clinic to investigate high-impact clinical applications and to support regulatory approval and U.S. commercialization of its Lumee continuous tissue oxygen monitoring technology. The agreement targets development of tethered continuous oxygen monitoring products for indications including cardiovascular, renal, multi-organ, orthopedic applications and critical limb ischemia. Mayo Clinic has a disclosed financial interest in the technology and will use any revenue to support its not-for-profit mission. No financial terms, timelines or specific regulatory milestones were disclosed.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Collaboration with Mayo Clinic, a major clinical and research institution</li><li>Focus on accelerating regulatory approval and U.S. commercialization of Lumee technology</li><li>Targeting multiple high-impact clinical indications including critical limb ischemia</li><li>Lumee described as a continuous, in-body tissue oxygen sensing platform; company is commercial-stage and reports >$100M invested in development</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>No financial terms, equity stakes, or commercialization timelines disclosed</li><li>Outcomes depend on future regulatory approvals and clinical validation</li><li>Press release contains forward-looking statements and associated risks and uncertainties</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/e3c3eee1-a793-4c4e-abfd-e1164690db6f" target="_blank">Original Article</a>
    </div>

    <div class="small">PFSA â€¢ TradersLink AI News</div>
  </div>
</body>
</html>